SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Alkermes Initiates Phase 2 Study of ALKS 7290

Alkermes said it has initiated a Phase 2 study of ALKS 7290 for major depressive disorder.

ALKS

Related stories